Prague Med. Rep. 2012, 113, 251-261
https://doi.org/10.14712/23362936.2015.8
Pharmacogenetics in Clinical Practice
References
1. Amos, C., Burke, W., Caskey, C. T. (2007) Applications of Toxicogenomic Technologies to Predictive Toxicology and Risk Assessment. National Academies Press, Washington D.C.
2. , M. L., Visser, L. E., van Schaik, R. H. N., Hofman, A., Uitterlinden, A. G., Stricker, B. H. Ch. (2011) OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 12, 79–82.
<https://doi.org/10.1007/s10048-010-0254-5>
<PubMed>
3. , M., Capogna, G., Stirparo, S., Berritta, C., Blouin, J. L., Landau, R. (2012) Effect of μ-opioid receptor A118G polymorphism on the ED50 of epidural sufentanil for labor analgesia. Int. J. Obstet. Anesth. 21(1), 40–44.
<https://doi.org/10.1016/j.ijoa.2011.10.001>
4. , L. P., Waterer, G., Thompson, P. J. (2011) Pharmacogenetics of β2 adrenergic receptor gene polymorphisms, long-acting β-agonists and asthma. Clin. Exp. Allergy 41(3), 312–326.
<https://doi.org/10.1111/j.1365-2222.2011.03696.x>
5. Cohen, N. (2008) Pharmacogenomics and Personalized Medicine. Humana Press, New York.
6. , K. R., Cross, S. J., McCormick, J. N., Baker, D. K., Molinelli, A. R., Mullins, R., Relling, M. V., Hoffman, J. M. (2011) Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am. J. Health Syst. Pharm. 68, 143–150.
<https://doi.org/10.2146/ajhp100113>
<PubMed>
7. , B. S., Gage, B. F., Johnson, J. A., Brensinger, C. M., Kimmel, S. E. (2011) Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol. 57(5), 612–618.
<https://doi.org/10.1016/j.jacc.2010.08.643>
<PubMed>
8. , G., Benítez, J., Carrillo, J. A. (2010) Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur. J. Pharmacol. 66, 755–774.
<https://doi.org/10.1007/s00228-010-0857-7>
9. , G. S., Willard, H. F. (2009) Genomic and personalized medicine: foundations and applications. Transl. Res. 154(6), 277–287.
<https://doi.org/10.1016/j.trsl.2009.09.005>
10. Harris, E. (1998) A Low-cost Approach to PCR. Oxford University Press, New York.
11. , M. (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25(4), 193–200.
<https://doi.org/10.1016/j.tips.2004.02.007>
12. Karsten, H. (2006) Gene Expression Profiling by Microarrays. Cambridge University Press, Cambridge.
13. Kliegman, R. M. (2007) Nelson Textbook of Pediatrics. Elsevier, Amsterdam.
14. , B., Schneider, K., Sittinger, K., Toennes, S. W., Seifried, E., Lindhoff-Last, E., Oldenburg, J., Geisen, C. (2011) Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thromb. Haemost. 105(1), 169–180.
<https://doi.org/10.1160/TH10-03-0194>
15. National Research Council (US), Committee on Applications of Toxicogenomic Technologies to Predictive Toxicology (2007) Applications of Toxicogenomic Technologies to Predictive Toxicology and Risk Assessment. National Academies Press, Washington D.C.
16. Passarge, E. (2001) Color Atlas of Pharmacogenetics. Thieme, Stuttgart.
17. , K. A., Veenstra, D. L., Oren, E., Lee, J. K., Sadee, W. (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270–2279.
<https://doi.org/10.1001/jama.286.18.2270>
18. , D., Rubinow, K. (2001) Pharmacogenomics of psychiatric disorders. Trends Pharmacol. Sci. 22(2), 75–83.
<https://doi.org/10.1016/S0165-6147(00)01603-5>
19. , R., Richterová, R. (2008) Farmakogenetika v laboratorní praxi. FONS informační bulletin 18, 20–23.
20. , W. (2011) Genomics and personalized medicine. Int. J. Pharm. 415, 2–4.
<https://doi.org/10.1016/j.ijpharm.2011.04.048>
21. , O., Didden, W. (2006) Budoucí možnosti genové terapie bolesti. Neurologie pro praxi 2, 90–93.
22. , O. (2005) Farmakogenetika v klinické praxi. Farmakoterapie 3, 296–298.
23. , O., Chalupna, P., Novotny, A., Botlik, M., Krska, Z., Caron, M. (2008) Fatal myelotoxicity after azathioprine treatment. Nucleosides Nucleotides Nucleic Acids 27(6/7), 661–665.
<https://doi.org/10.1080/15257770802143905>
24. , E., Lim, E. C. P., Teo, Y., Lim, Y., Law, H., Sia, A. T. (2009) Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Molecular Pain 5, 32.
<https://doi.org/10.1186/1744-8069-5-32>
<PubMed>
25. , S. M., Tantisira, K., Weiss, S. T. (2011) The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J. 11(6), 383–392.
<https://doi.org/10.1038/tpj.2011.46>
<PubMed>
26. , H., Stankova, M., Machala, L., Perlik, F., Slanar, O. (2011) Our experience with maraviroc treatment in HIV positive patients. Cas. Lek. Cesk. 150(8), 447–450. (in Czech)
27. , A. W., Bhathena, A., Gilardi, S., Mohr, D., Leong, D., Bienfait, K. L., Sarang, J., Duprey, S., Franc, M. A., Nelsen, A., Snapir, A. (2011) Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group. Clin. Pharmacol. Ther. 89(4), 529–536.
<https://doi.org/10.1038/clpt.2010.305>
